Gene Disease Score gda Association Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 1048
Gene Symbol: CEACAM5
CEACAM5
Secondary malignant neoplasm of colon and/or rectum
0.100 Biomarker BEFREE The purpose of this research is to perform a meta-analysis of the studies that evaluated the relationship between carcinoembryonic antigen (CEA) response and outcome in patients with mCRC receiving systemic chemotherapy. 30671635

2019

Entrez Id: 1048
Gene Symbol: CEACAM5
CEACAM5
Secondary malignant neoplasm of colon and/or rectum
0.100 Biomarker BEFREE The subgroup of PPTR with a low score (52.1 months) or intermediate score (26.2 months) had better OS than that of the Non-PPTR group (P < .001, P = .017, respectively).A novel scoring system composed of CEA, CA19-9, NLR, and LDH values is a feasible method to evaluate whether mCRC patients would benefit from PPTR. 31517873

2019

Entrez Id: 1048
Gene Symbol: CEACAM5
CEACAM5
Secondary malignant neoplasm of colon and/or rectum
0.100 Biomarker BEFREE To assess prognostic/predictive value of carcinoembryonic antigen (CEA), transthyretin (TRT), αenolase (NNE), β2-microglobulin (β2-micro), B-cell activating factor (BAFF) and circulating tumor cells (CTCs) in metastatic colorectal cancer (mCRC) patients treated with chemotherapy with or without bevacizumab. 28730771

2019

Entrez Id: 1048
Gene Symbol: CEACAM5
CEACAM5
Secondary malignant neoplasm of colon and/or rectum
0.100 Biomarker BEFREE Relevance of baseline carcinoembryonic antigen for first-line treatment against metastatic colorectal cancer with FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial). 30496943

2019

Entrez Id: 1048
Gene Symbol: CEACAM5
CEACAM5
Secondary malignant neoplasm of colon and/or rectum
0.100 Biomarker BEFREE Measurements of tumor markers, CEA and CA 19-9, in patients with metastatic colorectal cancer (<i>n</i> = 73) who received cetuximab plus folinic acid, fluorouracil, and oxaliplatin or irinotecan (FOLFOX4/FOLFIRI) as a first-line treatment at our center were retrospectively analyzed. 30805037

2019

Entrez Id: 1048
Gene Symbol: CEACAM5
CEACAM5
Secondary malignant neoplasm of colon and/or rectum
0.100 AlteredExpression BEFREE The aim of our retrospective study was to evaluate the association of baseline serum levels of carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA 19-9), thymidine kinase (TK) and tissue polypeptide specific antigen (TPS) with outcome of patients with mCRC treated with combination of chemotherapy and monoclonal antibodies against epidermal growth factor receptor (anti-EGFR mAbs) in the first line. 30519327

2018

Entrez Id: 1048
Gene Symbol: CEACAM5
CEACAM5
Secondary malignant neoplasm of colon and/or rectum
0.100 Biomarker BEFREE High baseline serum concentrations of CEA and CA 19-9 provide independent information of impaired prognosis in mCRC. 29872151

2018

Entrez Id: 1048
Gene Symbol: CEACAM5
CEACAM5
Secondary malignant neoplasm of colon and/or rectum
0.100 Biomarker BEFREE Our results show GDF-15 as an effective biomarker in patients with metastatic colorectal cancer with the same sensitivity as CEA. 29400662

2018

Entrez Id: 1048
Gene Symbol: CEACAM5
CEACAM5
Secondary malignant neoplasm of colon and/or rectum
0.100 Biomarker BEFREE Clinical Significance of Discordance between Carcinoembryonic Antigen Levels and RECIST in Metastatic Colorectal Cancer. 28494536

2018

Entrez Id: 1048
Gene Symbol: CEACAM5
CEACAM5
Secondary malignant neoplasm of colon and/or rectum
0.100 Biomarker BEFREE Can carcinoembryonic antigen replace computed tomography in response evaluation of metastatic colorectal cancer? 29388498

2018

Entrez Id: 1048
Gene Symbol: CEACAM5
CEACAM5
Secondary malignant neoplasm of colon and/or rectum
0.100 AlteredExpression BEFREE Serum CEA levels before the first curative hepatectomy for metastatic colorectal cancer seem to be a predictor of recurrence. 30194188

2018

Entrez Id: 1048
Gene Symbol: CEACAM5
CEACAM5
Secondary malignant neoplasm of colon and/or rectum
0.100 AlteredExpression BEFREE Progression-free and overall survival of 41 mCRC patients enrolled in the study correlated with baseline levels of CEA, immune-inflammatory markers (neutrophil/lymphocyte ratio, CRP, ESR, LDH, ENA), IL-4 and with post-treatment change in p-ANCA and CD56<sup>dim</sup>CD16<sup>bright</sup>NKs (<i>p</i> < 0.04). 29755670

2018

Entrez Id: 1048
Gene Symbol: CEACAM5
CEACAM5
Secondary malignant neoplasm of colon and/or rectum
0.100 Biomarker BEFREE Baseline serum OPG correlated with CEA (r=0.36, p=0.0011), but independently predicted survival of mCRC patients. 29402836

2018

Entrez Id: 1048
Gene Symbol: CEACAM5
CEACAM5
Secondary malignant neoplasm of colon and/or rectum
0.100 AlteredExpression BEFREE This study aimed to evaluate the significance of changes in systemic inflammatory markers and carcinoembryonic antigen (CEA) levels in predicting mCRC prognosis and chemotherapy response. 29044941

2018

Entrez Id: 1048
Gene Symbol: CEACAM5
CEACAM5
Secondary malignant neoplasm of colon and/or rectum
0.100 Biomarker BEFREE While the significance of carcinoembryonic antigen (CEA), lactate dehydrogenase (LDH), and Kirsten rat sarcoma (KRAS) status as individual prognostic factors for patients with metastatic colorectal cancer has been addressed, the relationship and interdependence between these prognostic factors on survival is limited. 28008623

2017

Entrez Id: 1048
Gene Symbol: CEACAM5
CEACAM5
Secondary malignant neoplasm of colon and/or rectum
0.100 Biomarker BEFREE Phase I/II Trial of Labetuzumab Govitecan (Anti-CEACAM5/SN-38 Antibody-Drug Conjugate) in Patients With Refractory or Relapsing Metastatic Colorectal Cancer. 28817371

2017

Entrez Id: 1048
Gene Symbol: CEACAM5
CEACAM5
Secondary malignant neoplasm of colon and/or rectum
0.100 GeneticVariation BEFREE Associations among the CEA decrease, depth of response (DpR), and clinical outcomes were evaluated in 113 patients with mCRC from two phase II trials of first-line therapy: the JACCRO CC-05 trial of cetuximab plus FOLFOX and the CC-06 trial of cetuximab plus SOX. 29064002

2017

Entrez Id: 1048
Gene Symbol: CEACAM5
CEACAM5
Secondary malignant neoplasm of colon and/or rectum
0.100 Biomarker BEFREE CEA response is associated with tumor response and survival in patients with KRAS exon 2 wild-type and extended RAS wild-type metastatic colorectal cancer receiving first-line FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial). 27234640

2016

Entrez Id: 1048
Gene Symbol: CEACAM5
CEACAM5
Secondary malignant neoplasm of colon and/or rectum
0.100 Biomarker BEFREE A phase 1/2 clinical trial evaluating dosing, safety, immunogenicity, and overall survival on metastatic colorectal cancer (mCRC) patients after immunotherapy with an advanced-generation Ad5 [E1-, E2b-]-CEA(6D) vaccine was performed. 25956394

2015

Entrez Id: 1048
Gene Symbol: CEACAM5
CEACAM5
Secondary malignant neoplasm of colon and/or rectum
0.100 Biomarker BEFREE Ad5 [E1-, E2b-]-CEA vaccine (ETBX-011) has been employed in clinical studies as an active vaccine to induce immune responses to CEA in metastatic colorectal cancer patients. 26374823

2015

Entrez Id: 1048
Gene Symbol: CEACAM5
CEACAM5
Secondary malignant neoplasm of colon and/or rectum
0.100 Biomarker BEFREE TIMP-1 and CEA as biomarkers in third-line treatment with irinotecan and cetuximab for metastatic colorectal cancer. 25608838

2015

Entrez Id: 1048
Gene Symbol: CEACAM5
CEACAM5
Secondary malignant neoplasm of colon and/or rectum
0.100 Biomarker BEFREE Carcinoembryonic antigen (CEA, CEACAM5) and epithelial cadherin (E-cadherin) are considered as independent tumor markers in monitoring metastatic colorectal cancer. 24726916

2014

Entrez Id: 1048
Gene Symbol: CEACAM5
CEACAM5
Secondary malignant neoplasm of colon and/or rectum
0.100 Biomarker BEFREE In the present study, we aimed to determine the prognostic role of initial CEA and CA 19-9 values in metastatic colorectal cancer patients according to the status of K-ras. 23625655

2013

Entrez Id: 1048
Gene Symbol: CEACAM5
CEACAM5
Secondary malignant neoplasm of colon and/or rectum
0.100 Biomarker BEFREE A randomized phase II study of immunization with dendritic cells modified with poxvectors encoding CEA and MUC1 compared with the same poxvectors plus GM-CSF for resected metastatic colorectal cancer. 23657083

2013

Entrez Id: 1048
Gene Symbol: CEACAM5
CEACAM5
Secondary malignant neoplasm of colon and/or rectum
0.100 Biomarker BEFREE T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. 21157437

2011